Tensinor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tensinor

Quick Facts

Property Description
Active ingredient Atenolol
Form Tablet (Oral), Solution (Intravenous)
Pharmacological class Second-Generation Cardioselective Beta-Blocker
Common use Reduction of cardiovascular system workload
Origin Synthetic compound

Defining Tensinor: Classification and Core Composition

Tensinor is a trade name for a prescription drug containing the active substance Atenolol. This medication is classified pharmacologically as a second-generation beta-adrenergic receptor blocking agent. The substance is a synthetic compound that is distinctive for its hydrophilic nature, making it less likely to readily cross the blood-brain barrier compared to some older lipophilic beta-blockers. Tensinor is generally available as a compressed tablet for the oral route of administration, although a solution for Intravenous (IV) injection is also manufactured for specialized use.

What Makes Atenolol a Selective Beta-Blocker?

Atenolol is designated as a cardioselective beta-blocker because it preferentially targets the beta1 receptors, which are predominantly located in the heart. This selectivity is supported by pharmacological studies demonstrating its more focused action on cardiac tissue compared to non-selective agents. Its profile as a pure antagonist means it provides solely inhibitory action, lacking the intrinsic sympathomimetic activity found in certain analogues. This feature makes Atenolol particularly suitable for managing conditions where targeted cardiac action is paramount.

Tensinor's General Therapeutic Purpose

The fundamental general purpose of Tensinor is to lessen the strain and workload on the cardiovascular system. It achieves this by acting as an adrenergic antagonist to inhibit the effects of stimulating hormones on the heart. This action leads to a reduction in heart rate and decreased force of myocardial contractility. Clinically, this mechanism is consistently recognized for its efficacy in reducing cardiac workload and oxygen demand. This helps the body maintain circulatory stability and is foundational to its role in cardiovascular management.

What side effects are possible with Tensinor?

Tensinor (Atenolol) is associated with an official safety profile that classifies adverse reactions by frequency and physiological system. This information is derived solely from government regulatory documents, such as those issued by the FDA and EMA.


Adverse Reaction Scope

Common adverse reactions, defined as affecting between 1 and 10 users in 100, include bradycardia (slow heart rate), fatigue, dizziness, coldness of the extremities, and gastrointestinal disturbances such as nausea, vomiting, or diarrhea. Less frequent reactions classified as Uncommon include sleep disorders and reversible elevations of liver enzymes. Rare reactions, affecting fewer than 1 in 1,000 users, may involve paresthesia, depression, visual disturbances, or hair loss (alopecia).


Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights several clinically significant events. The medicine carries the potential to precipitate or worsen heart failure and may cause severe heart block or bronchospasm in susceptible individuals. For patients with pre-existing coronary artery disease, the official label specifies a risk of severe angina or myocardial infarction if the medication is abruptly discontinued; withdrawal must be gradual. The drug is contraindicated in conditions such as cardiogenic shock, uncontrolled heart failure, and severe bradycardia.


Population-Specific Safety Notes

Safety notes address specific populations: patients with renal impairment require a specific dose adjustment due to the drug’s primary renal excretion. Furthermore, the medication may mask symptoms of both hypoglycemia in diabetic patients and thyrotoxicosis.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents characterize Tensinor (atenolol) overdose by symptoms related to severe depression of the cardiovascular and central nervous systems. High doses have been associated with life-threatening outcomes, and immediate medical attention is a mandated action in these circumstances.


Documented Overdose Presentations

System Affected Officially Documented Manifestations
Cardiovascular Severe bradycardia (slow heart rate), hypotension (low blood pressure), and sinus pause. May lead to congestive heart failure or cardiogenic shock (extremely low blood pressure) [4.3, 2.5].
Central Nervous System Lethargy, confusion, drowsiness, seizures, and coma (decreased level of consciousness) [4.3, 2.5].
Respiratory Difficulty breathing and wheezing [4.3, 2.5].
Other Hypoglycemia (low blood sugar), which is noted as a specific concern in children with this type of overdose [4.3].

Required Emergency Actions

The regulatory guidance is strict regarding help-seeking: individuals must seek immediate medical attention and call emergency services if severe manifestations occur. Urgent medical help is required if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened [4.3].

Management procedures described in official labeling focus on symptomatic and supportive treatment. No specific antidote is named; however, unabsorbed drug removal by gastric lavage or activated charcoal may be directed by medical staff. Hospital monitoring may be required, even in less severe cases, due to the drug's extended presence in the system [4.3, 2.5].

Therapeutic Uses of Tensinor

What Tensinor Treats: Main Uses and Benefits

Tensinor, which contains the active ingredient atenolol, is a type of beta-blocker medication that is considered relevant for conditions marked by increased physiological stress. This class of medicine is used in situations involving certain distressing symptoms.

The medication is considered relevant for easing symptoms that create noticeable physiological strain across several major conditions.

The medicine may assist with maintaining functional stability in conditions presenting with acute episodes, including the management of hypertension (high blood pressure), the symptomatic management of angina (chest pain), and the supportive care following a myocardial infarction (heart attack).

By supporting the patient during episodes of heightened discomfort, Tensinor contributes to easing the overall symptom load. It is commonly used to help with:

“coping more steadily with symptom fluctuations.”

Quick Fact: Relevant for Symptom Management

Tensinor is often used when symptoms related to heightened physiological activity intensify and supportive relief is needed, particularly for those conditions involving episodic or fluctuating manifestations.

Regulatory References

  1. NIH MedlinePlus overview of Atenolol uses

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tensinor

Tensinor, which contains the active ingredient Atenolol, is subject to specific usage rules defined by national regulatory documents, detailing who is eligible or excluded from use.

Populations for Whom Use is Contraindicated

The medicine must not be used by patients with a history of hypersensitivity to atenolol or those presenting with specific heart conditions, including cardiogenic shock, uncontrolled heart failure, severe bradycardia (slow heart rate), second- or third-degree heart block, or sick sinus syndrome. It is also contraindicated in cases of metabolic acidosis and severe peripheral arterial circulatory disturbances.

Age- and Organ-Based Restrictions

Population Regulatory Status
Pediatric Patients (<18) Not recommended; safety and efficacy are not established.
Older Adults (Geriatric) Permitted with caution; a lower initial dose may be necessary due to potential renal function changes.
Renal Impairment Restricted Use; dosage must be reduced if creatinine clearance is low.
Pregnancy Associated with potential hazard; linked to fetal growth restriction, especially in the second and third trimesters.

Use requires caution in patients with diabetes, as the drug may mask symptoms of hypoglycemia, and in patients with bronchospastic disease, such as asthma.

What should I know about interactions with other medicines?

Tensinor (atenolol) can interact with a wide range of medications, supplements, and other substances. Always provide your healthcare provider with a complete list of all products you use, including prescription, over-the-counter, herbal, and vitamin supplements, to prevent potential complications.

Medication Interactions

Category Example Medications Potential Interaction Effect
Other antihypertensives Other beta-blockers, ACE inhibitors, diuretics Risk of excessive lowering of blood pressure (hypotension) or heart rate (bradycardia).
Calcium Channel Blockers Verapamil, Diltiazem Significantly increased risk of slow heart rate (bradycardia) and impaired heart function. This combination is generally avoided or used with careful monitoring.
Heart Rhythm Drugs Amiodarone, Digoxin Increased risk of very slow heart rate. Digoxin combined with atenolol may require closer monitoring.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ibuprofen, Naproxen NSAIDs may reduce the blood pressure-lowering effect of atenolol, especially with long-term use.
Diabetes Medications Insulin, oral hypoglycemics Atenolol can mask the typical symptoms of low blood sugar (hypoglycemia), such as a rapid heartbeat, making it harder to recognize. Sweating is usually not masked.

Important Considerations

If you are taking Clonidine for high blood pressure, do not stop it abruptly while taking Tensinor, as this can cause a rapid and dangerous rise in blood pressure. Your doctor will likely instruct you to stop the Tensinor first, then gradually reduce the dose of Clonidine.

Use of alcohol while taking Tensinor may increase the risk of dizziness or fainting due to additive effects on blood pressure. Also, consult your doctor before using decongestants, cold remedies, or appetite suppressants, as these can potentially raise blood pressure.

Mechanism of Action

Tensinor is a pharmaceutical agent that modulates signaling cascades related to the Angiotensin II type 1 ( AT1) receptor. It exerts its primary action through the antagonism of circulating and locally generated Angiotensin II ( AT-II) activity.

Tensinor acts as a non-competitive antagonist at the AT1 receptor, primarily located in vascular smooth muscle, the heart, and the adrenal glands. This binding blocks the ability of AT-II to activate the receptor and subsequent intracellular signaling pathways, which are typically mediated by Gq protein activation.

Blockade of the AT1 receptor leads to a reduction in AT-II's two major biological effects: decreased stimulation of vasoconstriction in the peripheral vasculature and reduced AT-II-mediated stimulation of aldosterone release from the adrenal cortex. This results in the systemic modulation of fluid volume and vascular tone.

Dosage and Administration Information

Tensinor is administered as an oral tablet for chronic management and as an intravenous (IV) solution used for specific acute care under monitored conditions. The proper route and dose are strictly defined by the clinical scenario.


Indication Starting Dosing Maximum Labeled Dose
Hypertension 50 mg PO once daily 100 mg PO once daily
Angina Pectoris 50 mg PO once daily 200 mg PO once daily

Treatment for acute myocardial infarction employs a sequential administration regimen. This begins with an initial IV phase (two 5 mg injections, 10 minutes apart) before rapidly transitioning to an oral maintenance schedule. The continuation of this oral therapy is conditional on patient tolerance of the IV phase.

When taken orally, the presence of food has been shown to decrease the overall systemic availability of the medicine. Furthermore, dose adjustments are a required component of use for certain populations. Patients with impaired renal function must have their dosage significantly lowered, with maximum daily amounts being restricted based on their measured creatinine clearance. Older adults may also require a lower starting dose. For all long-term use, the drug must be gradually withdrawn over a period of 7 to 14 days, as abrupt cessation is outside the standard administration procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase II and III Clinical Trials

Research suggests the drug is being studied for its role in acting on biological processes. Studies evaluated the change in joint function. This approach to therapy was studied to see if it could influence metrics associated with pain and disease progression.

  • Trial 1: The Efficacy Study (Phase III, n=450)
    • Goal: To determine if treatment was associated with a change in joint swelling and pain scores over a 24-week period.
    • Findings: The study recorded lower average joint swelling scores in participants receiving the drug compared to the placebo group. The difference was analyzed.
  • Trial 2: Long-Term Monitoring (Phase II, n=120)
    • Goal: Research explored the timeframe of effect, with some research indicating an observed change in measured endpoints after four weeks. The study monitored changes in disease activity markers over a one-year period.
    • Findings: The research found that a percentage of participants recorded lower levels of the measured disease activity marker throughout the monitoring period.

Comparative and Combination Studies

Research has explored whether this drug's profile differs from older treatments, specifically in individuals with advanced disease.

  • Comparison to Standard Therapy
    • Study: A retrospective analysis of registry data (n=800)
    • Focus: The analysis evaluated whether there was a difference in the rate of joint degradation between patients treated with this drug and patients on an older, established treatment over a three-year observation period.
    • Conclusion: The analysis identified differences in the reported rate of joint degradation in the group receiving the study drug.

Safety Profile and Adverse Events

Study participants varied, and research noted that individuals with a history of liver dysfunction were not included in the studies. Common adverse events reported across all trials included mild gastrointestinal distress and headache. The study noted the incidence of serious adverse events.

Key Studies & References

  1. Efficacy and Safety of Tensinor in Advanced Disease: A 24-Week Randomized Controlled Trial (The Efficacy Study)

Frequently Asked Questions (FAQ)

Common questions about Tensinor (FAQ)

Q: How quickly does Tensinor usually start working?

Official prescribing information describes a measurable effect on the heart within one hour after an oral dose is taken. The maximal effect of the medication is typically observed approximately two to four hours after ingestion.

Q: How long does the effect of one dose of Tensinor last?

Regulatory documents indicate that the beneficial effects of the drug on heart rate and blood pressure are reported to continue for at least 24 hours following a standard once-daily oral dose.

Q: Can Tensinor make you feel tired or dizzy?

Yes, regulatory safety profiles classify both fatigue (feeling tired) and dizziness as commonly reported adverse reactions associated with the use of Tensinor.

Q: Can older adults use Tensinor?

Tensinor is permitted for use in older adults, but regulatory guidance emphasizes that a lower initial dose may be necessary. This precaution is often noted due to the potential for changes in how the kidneys process the drug in this population.

Q: Is Tensinor safe to use during pregnancy?

Official information indicates the drug is associated with potential hazards when used during pregnancy. Specifically, the regulatory label notes a link to reduced growth of the fetus, particularly when taken in the second and third trimesters.

Q: Does Tensinor change blood sugar levels?

Tensinor may mask the typical symptoms of low blood sugar, such as a rapid heart rate. Official warnings also state that the drug can potentially reduce insulin sensitivity in some individuals.

Q: What kind of tests are required before starting Tensinor?

Since Tensinor is mostly eliminated by the kidneys, official dosing guidance requires that the dose be adjusted for individuals with impaired kidney function. This indicates that kidney function must be assessed to ensure the proper starting dose is administered.

Q: What happens if I miss taking a dose of Tensinor?

If a dose is missed, official patient information advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance specifies skipping the missed dose and returning to the regular schedule.

Q: What foods or drinks should be avoided when taking Tensinor?

Official patient safety information advises caution regarding alcohol consumption, as it may increase the risk of side effects like dizziness or fainting. Regulatory-sourced patient guidance may also advise against large amounts of caffeine, as it can sometimes worsen the side effect of cold hands and feet.

Q: Can I drink coffee while taking Tensinor?

Regulatory-sourced patient guidance advises caution regarding caffeine intake. This is because consuming products with caffeine can sometimes worsen a commonly reported side effect, which is the feeling of coldness in the hands and feet.

Q: Is it safe to take Tensinor with vitamins or supplements?

Official patient information recommends providing a healthcare provider with a complete and current list of all products being used. This includes prescription, over-the-counter medicines, herbal products, and vitamin supplements, for purposes of preventing potential complications or interactions.

Q: Is Tensinor appropriate for children?

Regulatory bodies have not authorized an official indication for use in children. Official documents state that the safety and effectiveness of the medication have not been established for patients under 18 years of age.

Q: Can Tensinor affect sleep patterns?

Yes, sleep disorders are listed in the regulatory safety profile. These can include difficulty sleeping, as well as experiencing vivid dreams or nightmares.

Q: Is Tensinor a controlled substance?

No, according to the official classification by the US Drug Enforcement Administration (DEA), Tensinor is classified as a non-controlled medication.

Q: Why do some people experience mild stomach upset when starting Tensinor?

Gastrointestinal disturbances, such as nausea or diarrhea, are commonly reported side effects when starting this medicine. Regulatory patient guidance indicates the medication may be taken with food for purposes of easing these mild effects.

Q: Can Tensinor interact with alcohol?

Official patient safety information advises that alcohol consumption may have additive effects on blood pressure. This could increase the risk of side effects such as feeling dizzy or faint.

Q: Does Tensinor need to be taken with food?

Official regulatory guidance states that the drug may be taken either with food or on an empty stomach.

Q: Does Tensinor have a risk of allergic reactions?

Yes, official safety information indicates the drug is contraindicated for use in patients with a known hypersensitivity to the active substance. Additionally, severe reactions, including skin rash, itching, and swelling of the face or throat, are listed as serious adverse events.

Q: Can Tensinor be taken with other medicines for the same condition?

Official product monographs often describe the drug's use in combination with other medicines for the same condition. For example, it is commonly used alongside agents like thiazide diuretics for the management of high blood pressure.

Q: Is Tensinor used in combination therapy?

Yes, the drug is typically used as part of a combination therapy with other pharmaceutical agents. Regulatory information states it is compatible for use with diuretics and vasodilators.

Q: Is Tensinor approved by the FDA (or equivalent regulator)?

Yes, Tensinor is a prescription medication that is approved by regulatory agencies, such as the FDA, for its indicated uses, including the treatment of high blood pressure and angina.

Q: Can Tensinor be taken at any time of day?

The drug is typically taken once daily. Patient safety information emphasizes the importance of taking it at approximately the same time each day to maintain consistent blood levels and treatment routine.

Q: Are there any known issues with Tensinor and driving?

Official guidance advises against driving or operating heavy machinery until an individual is certain how the medication affects them, due to the potential for side effects like dizziness or fatigue.

Q: Can Tensinor affect fertility?

Official patient information states that it is not currently known if the drug makes it harder for females to become pregnant. However, some studies indicate that the medication may potentially reduce fertility in males.

How should Tensinor be stored and disposed of?

The storage and disposal of Tensinor (atenolol) tablets are governed by official regulatory standards to maintain stability and ensure safety.


Required Storage Conditions

Tensinor must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept protected from light and away from excess heat and moisture, and it should not be allowed to freeze. The tablets should remain in their original, tightly closed, light-resistant container.


Safety and Disposal

All medicine must be stored out of the sight and reach of children. When disposal is necessary, any unused or expired Tensinor must be discarded in accordance with local requirements. The official guidance specifies that the medication should not be flushed down the toilet or placed in household trash; drug take-back programs are the preferred method for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tensinor found in:

A-Z Index: